Scientific Program

PROGRAMME SCHEDULE

Time shown in IST (Indian Standard Time)

DAY-1: Thursday, 1^stSEPTEMBER, 2023

1:00 to 1:05 PM	Prayer by Chaplain
1:05 to 1:20 PM	Welcome remarks: Dr. J V Peter, Director, CMC / Dr. Maneesha Inamdar, Director, inStem / Dr. Solomon Satishkumar, Principal, CMC
1:20 to 1:30 PM	Closing remarks: Dr. Alok Srivastava, Head, CSCR

Session-1: APPLICATIONS OF iPSC TECHNOLOGY Chair- Maneesha S. Inamdar
Indian Time	Title	Speaker Name
1.30 to 2:00PM	Consistency and reliability of quality testing for induced Pluripotent Stem Cells	Stephen Sullivan Global Alliance for iPSC Therapies, UK
2:00 to 2:30PM	Assuring reproducibility: Sharing data on hPSC – lines and clinical trials	Andreas Kurtz Charité-Universitäts Medizin Berlin and Fraunhofer Institute for Biomedical Engineering, Sulzbach, Germany
2:30 to 3:00PM	Creation of a Haplobank- Initiative in India	Dolly Daniel Christian Medical College and Centre for Stem Cell Research, Vellore, India
3:00 to 3:15PM	Break
3:15 to 3:45PM	Poster presentation
Session-2: IMMUNE CELL THERAPY Chair- Navin Khattry
Indian Time	Title	Speaker Name
3:45 to 4:15 PM	CAR-T cell therapy in relapsed/ refractory DLBCL	Hasmukh Jain Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, India
4:15 to 4:45 PM	CAR-T cell therapy for haematological malignancies or solid tumours	Avery D. Posey University of Pennsylvania, Philadelphia USA
4:45 to 5:15 PM	Donor derived anti-3rd party CD8 T Cells in haploidentical stem cell transplantation and immune cell therapy	Aloukick Kumar Singh Centre for Stem Cell Research, Vellore, India
5:15 to 5:30PM	Break
Session-3: GENE THERAPY Chair- Soniya Nityanand
Indian Time	Title	Speaker Name
5:30 to 6:00PM	Nongenotoxic conditioning for transplant of genetically engineered HSCs: Is this the future for HSC-based gene therapy	H. Trent Spencer Emory University School of Medicine, Atlanta, USA
6:00 to 6:30PM	Gene Therapy for Hemophilia A – What are the current options?	Alok Srivastava Christian Medical College and Centre for Stem Cell Research, Vellore, India
6:30 to 7:00PM	Gene Therapy for Platelet Derived Factor VIII Production in Hemophilia A	David Wilcox Medical College of Wisconsin, WI, US
KEYNOTE ADDRESS Chair- Alok Srivastava
Indian Time	Title	Speaker Name
7:00 to 8:00 PM	Developing New Transformative Approaches to Genetic Engineering of Hematopoiesis	Luigi Naldini San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milano, Italy
End of Day-1

DAY-2: Friday, 2^ndSEPTEMBER, 2022
Session-4: TECHNOLOGY ADVANCES Chair- Udaykumar Ranga
Indian Time	Title	Speaker Name
2:00 to 2:30 PM	Assessing and mitigating off-target effects in therapeutic genome editing	Toni Cathomen Institute for Transfusion Medicine and Gene Therapy, Germany
2:30 to 3:00 PM	Precise modelling and correction of a spectrum of β-thalassaemia mutations in human erythroid cells by base editors	Mohankumar Murugesan Centre for Stem Cell Research, Vellore, India
3:00 to 3:30 PM	IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies	Sebastien Lacroix-Desmazes Centre de Recherche des Cordeliers, France
3:30 to 4:00 PM	Development of optimized (“Opt”) and generation Y (“GenY”) AAVrh74 vectors for gene therapy of muscular dystrophies	Arun Srivastava University of Florida, Florida , USA
4:00 to 4:15 PM	Break
Session-5: Industry Symposium Chair- Cartikeya Reddy
Indian Time	Title	Speaker Name
4:15 to 4:45 PM	Cell therapy solutions for every step – from discovery to cure	Prathap Naidu Thermo Fisher Scientific, Hyderabad, India
4:45 to 5:15PM	Droplet Digital PCR for Cell and Gene Therapy — ddPCR resolves problems with qPCR	Ajay Deepak Baskaran Bio-Rad Laboratories (India) Pvt Ltd., Haryana, India
5:15 to 6:00 PM	Poster presentation
Session-6: MANUFACTURING AND REGULATORY ASPECTS IN CELL AND GENE THERAPY Chair- Cartikeya Reddy
Indian Time	Title	Speaker Name
6:00 to 6:30 PM	Manufacturing of Lentiviral Vector (LV) for Haemophilia A Lentiviral mediated genetic modification of HSC from Haemophilia A patients	William Swaney Expression Manufacturing LLC, Georgia, USA Gurbind Singh Centre for Stem Cell Research, Vellore, India
6:30 to 7:00 PM	Advanced HSC clinical trials in the Necker hospital GMP facility	Elisa Magrin & Jihene Benlagha Necker-Enfants Malades Hospital, Paris, France
7:00 to 7:30 PM	Virus-specific T Cell Engineering for Clinical Applications	Adrian Gee Center for Cell & Gene Therapy, Baylor College of Medicine Houston, TX, US
KEYNOTE ADDRESS Chair-RV Shaji
Indian Time	Title	Speaker Name
7:30 to 8:30 PM	Evolution of lentiviral vector mediated gene modified autologous HSCs for the treatment of hemoglobin disorders	Mark C. Walters UCSF Benioff Children’s Hospitals, California, USA
End of Day-2

DAY-3: Saturday, 3^rdSEPTEMBER, 2022
Session-7: CELL AND GENE THERAPY- INDUSTRY UPDATES Chair- Vijay Chandru
Indian Time	Title	Speaker Name
2:00 to 2:30 PM	Future of Vaccinology-mRNA	Ajay Singh Gennova Biopharma Ltd., Pune, India
2:30 to 3:00 PM	CAR-T cell Therapy-Bench to Bedside-the Immuneel approach	Anil Kamat Immuneel Therapeutics Private Limited, Bangalore, India
3:00 to 3:30 PM	Allogeneic, Off the Shelf, Pooled, Bone marrow derived Mesenchymal Stromal Cells (Stempeucel®) – a Potential break through therapy for Grade II & III Osteoarthritis knee	Pawan Kumar Gupta Stempeutics Research Pvt. Ltd., Bangalore, India
3:30 to 3:45 PM	Break
Session-8: GENE EDITING Chair- Souvik Maiti
Indian Time	Title	Speaker Name
3:45 to 4:15 PM	A Mutation-Agnostic Hematopoietic Stem Cell Gene editing approach	Justin S Antony University of Tübingen, Germany
4:15 to 4:45 PM	Genome editing approaches for beta-hemoglobinopathies	Annarita Miccio Institute of genetic diseases Imagine, INSERM UMR1163, Universite’ Paris Cite’ Paris, France
4:45 to 5:15 PM	The CD34+CD90+HSCs as a target cell for CCR5 gene editing	Saravanabhavan Thangavel Centre for Stem Cell Research, Vellore, India
5:15 to 6:00 PM	Poster presentation
Session-9: NON-VIRAL NUCLEIC ACID TRANSFER Chair- Arabinda Chaudhuri
Indian Time	Title	Speaker Name
6:00 to 6:30 PM	Smart lipid nanoparticle enabled mRNA vaccine for SARS-CoV2	Srujan Marepally Centre for Stem Cell Research, Vellore, India
6:30 to 7:00 PM	Engineering mesenchymal stem cells by modulating tissue factor gene expression using short interfering RNA	Oommen P. Oommen Faculty of Medicine and Health Technology, Tampere University, Finland,
7:00 to 7:30 PM	Boosting intracellular delivery of mRNA therapeutics and its applications	Gaurav Sahay Oregon State University, Oregon, US
End of Day-3